ACCUNEB
Clinical safety rating
cautionComprehensive clinical and safety monograph for ACCUNEB (ACCUNEB).
Comprehensive clinical and safety monograph for ACCUNEB (ACCUNEB).
Treatment or prevention of bronchospasm in patients with reversible obstructive airway diseaseAcute prophylaxis against exercise-induced bronchospasm
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.
| Metabolism | Metabolized primarily by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfatase enzymes in the gastrointestinal tract. |
| Excretion | Renal: ~70% as unchanged drug and active metabolite (N-acetylprocainamide) within 24 hours; biliary/fecal: minimal (<5%) |
| Half-life | 2-5 hours (procainamide); 6-8 hours (N-acetylprocainamide); prolonged in renal impairment (up to 20 hours) |
| Protein binding | 15-20% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.5-2.5 L/kg; distributes widely into tissues with high affinity for cardiac tissue |
| Bioavailability | Oral immediate-release: 75-95%; IM: 100%; IV: 100% |
| Onset of Action | IM: 10-30 min; IV: 5-10 min; Oral: 30-60 min |
| Duration of Action | 3-4 hours (immediate-release); 6-12 hours (extended-release); antiarrhythmic effect persists as long as therapeutic serum levels maintained |
| Molecular Weight | 336.41 |
Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required; drug undergoes minimal renal excretion. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for systemic accumulation. |
| Liver impairment | No specific dose adjustment for Child-Pugh Class A or B. For Child-Pugh Class C, consider dose reduction by 50% due to reduced clearance. |
| Pediatric use | Children 2-12 years: Nebulized solution 0.31 mg, 0.63 mg, or 1.25 mg three times daily every 6-8 hours based on severity. For children ≥12 years, same as adult dosing. |
| Geriatric use | Start at lower end of dosing range (0.63 mg three times daily) due to potential age-related renal impairment and increased sensitivity to beta-agonists. Monitor for tachycardia and tremors. |
| 1st trimester | Limited human data; animal studies show no evidence of teratogenicity but caution is advised. Use only if potential benefit outweighs risk. |
| 2nd trimester | May be used if clearly needed. Monitor for fetal tachycardia or hypoglycemia. |
| 3rd trimester | May cause uterine relaxation and delay labor; use near term with caution. Possible neonatal effects include jitteriness, hypoglycemia. |
Clinical note
Comprehensive clinical and safety monograph for ACCUNEB (ACCUNEB).
| Placental transfer | Crosses placenta; evidence from human studies shows measurable concentrations in fetal blood. |
| Breastfeeding | Excreted into breast milk in low concentrations. Monitor infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). Compatible with breastfeeding with caution. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | ACCUNEB (levalbuterol) is a beta-2 adrenergic agonist. Based on animal studies and human data, there is no evidence of teratogenicity. However, during the second and third trimesters, beta-agonists may cause fetal tachycardia, hypoglycemia, and hypocalcemia. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum potassium. Fetal monitoring may be considered for signs of tachycardia or distress in cases of high-dose or prolonged use. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data are limited. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to levalbuterol or any componentPre-existing cardiac arrhythmias (e.g., tachyarrhythmias)
| Precautions | Paradoxical bronchospasm, Cardiovascular effects including increased heart rate and blood pressure, Hypokalemia, Immediate hypersensitivity reactions |
| Food/Dietary | No specific food interactions. Avoid caffeine and other stimulants as they may increase side effects like nervousness and rapid heartbeat. |
| Clinical Pearls | ACCUNEB (levalbuterol) is the R-isomer of albuterol, designed to reduce beta-adrenergic side effects. It is preferred in patients with tachycardia or sensitivity to beta-agonists. Monitor for paradoxical bronchospasm; discontinue immediately if occurs. Nebulized solution should be used with a jet nebulizer connected to an air compressor. Not for acute deterioration unless patient is already on regular therapy. |
| Patient Advice | Use only as prescribed; do not increase dose or frequency without consulting your doctor. · Shake the nebulizer solution well before use. Do not mix with other medications unless instructed. · If you experience worsening breathing, chest tightness, or hives, stop the medication and seek medical help immediately. · Rinse mouth with water after each use to prevent throat irritation and thrush. · Store at room temperature away from light and moisture. Do not freeze. |
Loading safety data…